MENU

Metabolomics Technology Applied to Diabetes Research

11/30/10

Metabolomics Technology Applied to Diabetes Research

RESEARCH TRIANGLE PARK, N.C. (November 30, 2010) — Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announces the publication of “Metabolic Footprint of Diabetes: A Multiplatform Metabolomics Study in an Epidemiological Setting” in PLoS ONE.

Data from Metabolon’s non-targeted biochemical profiling platform was combined with data collected from targeted metabolomics platforms to identify metabolic signatures that are associated with Type 2 diabetes. The proof of concept study illustrates the value of using metabolomics to identify biochemical pathways affected by Type 2 diabetes. The authors show that functional metabolomics can contribute to the development of a more sophisticated classification of the disease and lead to optimized diagnosis and treatment options.

Copies of the paper can be accessed from PLoS ONE: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0013953

About Metabolon
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com or contact Matt Zaske mzaske@metabolon.com at (919) 595-2200.